ClinicalTrials.gg
CompletedNCT02926833ZUMA-6Updated Mar 6, 2024Results posted

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 1/2 interventional study of KTE-C19 and Atezolizumab in Refractory Diffuse Large B Cell Lymphoma, sponsored by Kite, A Gilead Company. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Gilead Sciences.

Enrollment
8th of 10
37 · median 63
Started
2016
the only one that year
Phase 1/2
4 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 4 in phase 1/2, and was the 8th registered.

Lymphoma, Large B-Cell, Diffuse

1,870 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences as a file.
02

Study summary

The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens.

The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL).

Participants who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).

03

Conditions studied

  • Refractory Diffuse Large B Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed DLBCL
  2. Chemotherapy- disease, defined as one or more of the following:

    • Stable disease (duration of stable disease must be less than or equal to 6 months) or progressive disease as best response to most recent chemotherapy containing regimen
    • Disease progression or recurrence less than or equal to 12 months of prior stem cell transplantation (SCT)
  3. Individuals must have received adequate prior therapy including at a minimum:

    • Anti-cluster of differentiate 20 (anti-CD20) monoclonal antibody unless investigator determines that tumor is CD20-negative; and
    • an anthracycline containing chemotherapy regimen
  4. At least one per revised International Working Group (IWG) Response Criteria
  5. Age 18 years or older
  6. (ECOG) performance status of 0 or 1
  7. Adequate organ and bone marrow function
  8. All individuals or legally appointed representatives/caregivers, must personally sign and date the institutional review board (IRB)/independent ethics committee (IEC) approved consent form before initiating any study specific procedures or activities.

Key Exclusion Criteria:

  1. History of other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years
  2. History of allogeneic stem cell transplantation
  3. Prior CAR therapy or other genetically modified T cell therapy
  4. active infection
  5. Known history of infection with (HIV) or (HBsAg positive) or virus (anti-HCV positive)
  6. Individuals with detectable cerebrospinal fluid malignant cells or or with a history of cerebrospinal fluid malignant cells or brain metastases
  7. History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any disease with central nervous system (CNS) involvement
  8. History of autoimmune disease. Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and participants with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study.
  9. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computed tomography (CT) scan at screening. History of radiation pneumonitis in the radiation field (fibrosis) is allowed.
  10. Prior treatment with Programmed Cell Death Ligand 1 () inhibitor, PD-1 inhibitor, anti-CTLA4, anti-CD137, anti-OX40 or other immune checkpoint blockade or activator therapy with the exception of Individuals who received atezolizumab in this study and are eligible for re-treatment
  11. Prior CD19 targeted therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Phase 1 Cohort 1: KTE-C19 + ATZ (After 21 Days of KTE-C19)

    Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide intravenous (IV) infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg followed by 4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days, beginning 21 days following KTE-C19.

    Biological: KTE-C19 · Biological: Atezolizumab · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Phase 1 Cohort 2: KTE-C19 + ATZ (After 14 Days of KTE-C19)

    Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 14 days following KTE-C19.

    Biological: KTE-C19 · Biological: Atezolizumab · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Phase 1 Cohort 3: KTE-C19 + ATZ (After 1 Day of KTE-C19)

    Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 1 day following KTE-C19.

    Biological: KTE-C19 · Biological: Atezolizumab · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Phase 2: KTE-C19 + ATZ (After 1 Day of KTE-C19)

    Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 1 day following KTE-C19.

    Biological: KTE-C19 · Biological: Atezolizumab · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

  • BiologicalKTE-C19

    A single infusion of KTE-C19 CAR-T cells administered intravenously

    Also known as: Axicabtagene ciloleucel, Yescarta®

  • BiologicalAtezolizumab

    Administered intravenously

  • Administered intravenously

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)

    A DLT was defined as the following KTE-C19-related or ATZ-related events with an onset from immediately after the first ATZ infusion through 21 days after the first ATZ infusion: Grade 4 hematologic toxicity lasting \> 30 days (except lymphopenia or B-cell aplasia); All KTE-C19- or ATZ-related Grade 3 non-hematologic toxicities lasting for \> 7 days and all KTE-C19- or ATZ-related Grade 4 non-hematologic toxicities regardless of duration.

    Time frame: Baseline up to 21 days

  2. Phase 1 and 2: Complete Response Rate (CRR)

    CRR was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a complete response (CR) as assessed by the study investigators. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease.

    Time frame: From enrollment until first occurrence of CR or PR (maximum duration: 6.2 years)

Secondary outcomes

  1. Phase 1 and 2: Objective Response Rate (ORR)

    ORR was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a CR or partial response (PR) as assessed by the study investigators. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. Participants who did not meet the criteria for objective response by the analysis cutoff date were considered non-responders.

    Time frame: From enrollment until first occurrence of CR or PR (maximum duration: 6.2 years)

  2. Phase 1 and 2: Duration of Response (DOR)

    DOR for participants who experienced an objective response was defined as the date of their first confirmed objective response (CR or PR) to disease progression per the revised International Working Group Response Criteria for Malignant Lymphoma (Cheson, 2007) or death regardless of cause. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined at least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses. Disease progression was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir. The Kaplan-Meier approach was used to estimate DOR.

    Time frame: From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (maximum duration: 6.2 years)

  3. Phase 1 and 2: Progression-Free Survival (PFS)

    PFS was defined as the time from the KTE-C19 infusion date to the date of disease progression per the revised International Working Group Response Criteria for Malignant Lymphoma (Cheson, 2007) or death from any cause. Disease progression was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir. The Kaplan-Meier approach was used to estimate PFS.

    Time frame: From the date of first KTE-C19 infusion to disease progression or death regardless of cause (maximum duration: 6.2 years)

  4. Phase 1 and 2: Overall Survival (OS)

    OS was defined as the time from KTE-C19 infusion to the date of death from any cause. The Kaplan-Meier approach was used to estimate OS.

    Time frame: From the date of first KTE-C19 infusion to the date of death regardless of cause (maximum duration: 6.2 years)

  5. Phase 1 and 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    An adverse event was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. Adverse events included worsening of a pre-existing medical condition. Worsening indicated that the pre-existing medical condition had increased in severity, frequency, and/or duration or had an association with a worse outcome. A pre-existing condition that had not worsened during the study or involved an intervention such as elective cosmetic surgery or a medical procedure while in study, was not considered an adverse event. TEAEs included all AEs with onset on or after initiation of axicabtagene ciloleucel.

    Time frame: Up to 1.8 years

  6. Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values

    Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date. ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase.

    Time frame: Up to 1.8 years

  7. Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values

    Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.

    Time frame: Up to 1.8 years

  8. Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values

    Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.

    Time frame: Up to 1.8 years

  9. Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values

    Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.

    Time frame: Up to 1.8 years

  10. Phase 1 and 2: Peak Anti-CD19 CAR T-Cell (KTE-C19) Level (Maximum Observed Plasma Concentration) in Blood

    Time frame: Pre-infusion (Baseline); Post-infusion: Days 7 (Phase 2), 14, 22 (Phase 2), 28 (Phase 2; optional), 35 (Phase 1, Cohort 3; optional), 43, 49 (optional), 64, 69 (optional), 94; long-term follow-up: every 3 months from Month 6 to Month 18, and Month 24

  11. Phase 1 and 2: Percentage of Participants With Anti-KTE-C19 Antibodies

    Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, 14, 22 , 28, Day 35, 49, 69, and 94 post-KTE-C19 infusion

  12. Phase 1 and 2: Atezolizumab Levels in Blood

    Time frame: Days 1, 14, 21, 22, 35, 42, 43, 56, 63, 64, 77, 84, 154, and 174

  13. Phase 1 and 2: Percentage of Participants With Anti-Atezolizumab Antibodies

    Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, 14, 22 , 28, Day 35, 49, 69, and 94 post-KTE-C19 infusion

  14. Phase 1 and 2: Peak Serum Levels of C-Reactive Protein (CRP) in Blood

    Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion

  15. Phase 1 and 2: Peak Serum Levels of C-X-C Motif Chemokine 10 (CXCL10), Interferon-Gamma (IFN-γ), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin (IL)-2, IL-6, IL-8, IL-15, and Tumor Necrosis Factor-Alpha (TNF-α) in Blood

    Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion

  16. Phase 1 and 2: Peak Serum Levels of Ferritin in Blood

    Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion

  17. Phase 1 and 2: Peak Serum Levels of Interleukin-2 Receptor Alpha (IL-2Rα) in Blood

    Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion

07

Results

Posted Jun 26, 2020

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestonePhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Started34723
Completed1010
Not completed24623
Withdrew: Death11213
Withdrew: Lost to follow-up1203
Withdrew: Full consent withdrawal0002
Withdrew: Rolled over to long-term follow-up study0034
Withdrew: Investigator decision0100
Withdrew: Adverse event0010
Withdrew: Partial withdrawal of consent0001

Outcome measures

PrimaryPhase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)

A DLT was defined as the following KTE-C19-related or ATZ-related events with an onset from immediately after the first ATZ infusion through 21 days after the first ATZ infusion: Grade 4 hematologic toxicity lasting \> 30 days (except lymphopenia or B-cell aplasia); All KTE-C19- or ATZ-related Grade 3 non-hematologic toxicities lasting for \> 7 days and all KTE-C19- or ATZ-related Grade 4 non-hematologic toxicities regardless of duration.

Time frame:
Baseline up to 21 days
Reported as:
Count of participants · Participants
Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
ParticipantsPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)
Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)001
PrimaryPhase 1 and 2: Complete Response Rate (CRR)

CRR was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a complete response (CR) as assessed by the study investigators. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease.

Time frame:
From enrollment until first occurrence of CR or PR (maximum duration: 6.2 years)
Reported as:
Number · percentage of participants
Phase 1 and 2: Complete Response Rate (CRR)
percentage of participantsPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
Phase 1 and 2: Complete Response Rate (CRR)54 (34 to 72)
SecondaryPhase 1 and 2: Objective Response Rate (ORR)

ORR was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a CR or partial response (PR) as assessed by the study investigators. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. Participants who did not meet the criteria for objective response by the analysis cutoff date were considered non-responders.

Time frame:
From enrollment until first occurrence of CR or PR (maximum duration: 6.2 years)
Reported as:
Number · percentage of participants
Phase 1 and 2: Objective Response Rate (ORR)
percentage of participantsPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
Phase 1 and 2: Objective Response Rate (ORR)75 (55 to 89)
SecondaryPhase 1 and 2: Duration of Response (DOR)

DOR for participants who experienced an objective response was defined as the date of their first confirmed objective response (CR or PR) to disease progression per the revised International Working Group Response Criteria for Malignant Lymphoma (Cheson, 2007) or death regardless of cause. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined at least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses. Disease progression was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir. The Kaplan-Meier approach was used to estimate DOR.

Time frame:
From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (maximum duration: 6.2 years)
Reported as:
Median · months
Phase 1 and 2: Duration of Response (DOR)
monthsPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
Phase 1 and 2: Duration of Response (DOR)41.4 (1.8 to NA)
SecondaryPhase 1 and 2: Progression-Free Survival (PFS)

PFS was defined as the time from the KTE-C19 infusion date to the date of disease progression per the revised International Working Group Response Criteria for Malignant Lymphoma (Cheson, 2007) or death from any cause. Disease progression was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir. The Kaplan-Meier approach was used to estimate PFS.

Time frame:
From the date of first KTE-C19 infusion to disease progression or death regardless of cause (maximum duration: 6.2 years)
Reported as:
Median · months
Phase 1 and 2: Progression-Free Survival (PFS)
monthsPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
Phase 1 and 2: Progression-Free Survival (PFS)9 (3.1 to NA)
SecondaryPhase 1 and 2: Overall Survival (OS)

OS was defined as the time from KTE-C19 infusion to the date of death from any cause. The Kaplan-Meier approach was used to estimate OS.

Time frame:
From the date of first KTE-C19 infusion to the date of death regardless of cause (maximum duration: 6.2 years)
Reported as:
Median · months
Phase 1 and 2: Overall Survival (OS)
monthsPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
Phase 1 and 2: Overall Survival (OS)32.2 (11.6 to NA)
SecondaryPhase 1 and 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

An adverse event was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. Adverse events included worsening of a pre-existing medical condition. Worsening indicated that the pre-existing medical condition had increased in severity, frequency, and/or duration or had an association with a worse outcome. A pre-existing condition that had not worsened during the study or involved an intervention such as elective cosmetic surgery or a medical procedure while in study, was not considered an adverse event. TEAEs included all AEs with onset on or after initiation of axicabtagene ciloleucel.

Time frame:
Up to 1.8 years
Reported as:
Number · percentage of participants
Phase 1 and 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Phase 1 and 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)100100100100
SecondaryPhase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values

Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date. ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase.

Time frame:
Up to 1.8 years
Reported as:
Number · percentage of participants
Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values
percentage of participantsPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Shift to Grade 3 ALT0005
Shift to Grade 4 ALT0005
Shift to Grade 3 ALP00014
Shift to Grade 3 AST0009
Shift to Grade 4 AST0005
Shift to Grade 3 bilirubin0009
Shift to Grade 4 calcium0005
Shift to Grade 3 creatinine0009
Shift to Grade 4 creatinine0005
Shift to Grade 3 direct bilirubin33331714
Shift to Grade 3 glucose00018
Shift to Grade 4 glucose00014
SecondaryPhase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values

Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.

Time frame:
Up to 1.8 years
Reported as:
Number · percentage of participants
Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values
percentage of participantsPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Shift to Grade 3 albumin33009
Shift to Grade 3 calcium33005
Shift to Grade 4 calcium00018
Shift to Grade 3 phosphate67673336
Shift to Grade 4 phosphate00036
Shift to Grade 3 potassium00014
Shift to Grade 3 sodium6701714
Shift to Grade 4 glucose00170
SecondaryPhase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values

Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.

Time frame:
Up to 1.8 years
Reported as:
Number · percentage of participants
Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values
percentage of participantsPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values0000
SecondaryPhase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values

Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.

Time frame:
Up to 1.8 years
Reported as:
Number · percentage of participants
Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values
percentage of participantsPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Shift to Grade 3 hemoglobin100678359
Shift to Grade 3 leukocytes003318
Shift to Grade 4 leukocytes1001006777
Shift to Grade 4 lymphocytes10010010086
Shift to Grade 3 neutrophils0331714
Shift to Grade 4 neutrophils100678373
Shift to Grade 3 platelets3301718
Shift to Grade 4 platelets33671732
SecondaryPhase 1 and 2: Peak Anti-CD19 CAR T-Cell (KTE-C19) Level (Maximum Observed Plasma Concentration) in Blood
Time frame:
Pre-infusion (Baseline); Post-infusion: Days 7 (Phase 2), 14, 22 (Phase 2), 28 (Phase 2; optional), 35 (Phase 1, Cohort 3; optional), 43, 49 (optional), 64, 69 (optional), 94; long-term follow-up: every 3 months from Month 6 to Month 18, and Month 24
Reported as:
Mean · cells/μL
Phase 1 and 2: Peak Anti-CD19 CAR T-Cell (KTE-C19) Level (Maximum Observed Plasma Concentration) in Blood
cells/μLPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Phase 1 and 2: Peak Anti-CD19 CAR T-Cell (KTE-C19) Level (Maximum Observed Plasma Concentration) in Blood86.87 ± 67.17167.88 ± 91.5860.71 ± 70.6660.22 ± 60.24
SecondaryPhase 1 and 2: Percentage of Participants With Anti-KTE-C19 Antibodies
Time frame:
Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, 14, 22 , 28, Day 35, 49, 69, and 94 post-KTE-C19 infusion
Reported as:
Number · percentage of participants
Phase 1 and 2: Percentage of Participants With Anti-KTE-C19 Antibodies
percentage of participantsPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Phase 1 and 2: Percentage of Participants With Anti-KTE-C19 Antibodies0000
SecondaryPhase 1 and 2: Atezolizumab Levels in Blood
Time frame:
Days 1, 14, 21, 22, 35, 42, 43, 56, 63, 64, 77, 84, 154, and 174
Reported as:
Mean · ng/mL
Phase 1 and 2: Atezolizumab Levels in Blood
ng/mLPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Day 1——373000 ± 65300328000 ± 89100
Day 14—435000 ± 61500——
Day 21403000 ± 46100———
Day 22——73900 ± 27900110000 ± 126000
Day 35—84200 ± 14300——
Day 4298800 ± 16500———
Day 43——138000 ± 78700136000 ± 69900
Day 56—176000 ± 2828.43——
Day 63175000 ± 7505.55———
Day 64——159000 ± 91600185000 ± 88700
Day 77—240000 ± 33000——
Day 84209000 ± 24800———
Day 154——1360066800 ± 58900
Day 17491000———
SecondaryPhase 1 and 2: Percentage of Participants With Anti-Atezolizumab Antibodies
Time frame:
Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, 14, 22 , 28, Day 35, 49, 69, and 94 post-KTE-C19 infusion
Reported as:
Number · percentage of participants
Phase 1 and 2: Percentage of Participants With Anti-Atezolizumab Antibodies
percentage of participantsPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
Phase 1 and 2: Percentage of Participants With Anti-Atezolizumab Antibodies0000
SecondaryPhase 1 and 2: Peak Serum Levels of C-Reactive Protein (CRP) in Blood
Time frame:
Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion
Reported as:
Median · mg/L
Phase 1 and 2: Peak Serum Levels of C-Reactive Protein (CRP) in Blood
mg/LPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
Phase 1 and 2: Peak Serum Levels of C-Reactive Protein (CRP) in Blood174.03 (51.78 to 496.00)
SecondaryPhase 1 and 2: Peak Serum Levels of C-X-C Motif Chemokine 10 (CXCL10), Interferon-Gamma (IFN-γ), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin (IL)-2, IL-6, IL-8, IL-15, and Tumor Necrosis Factor-Alpha (TNF-α) in Blood
Time frame:
Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion
Reported as:
Median · pg/mL
Phase 1 and 2: Peak Serum Levels of C-X-C Motif Chemokine 10 (CXCL10), Interferon-Gamma (IFN-γ), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin (IL)-2, IL-6, IL-8, IL-15, and Tumor Necrosis Factor-Alpha (TNF-α) in Blood
pg/mLPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
CXCL 102000.00 (444.80 to 2000.00)
IFN-γ587.80 (15.60 to 1876.00)
IL-1RA2469.60 (541.40 to 9000.00)
IL-217.55 (1.80 to 152.70)
IL-6121.55 (4.30 to 976.00)
IL-8180.65 (18.60 to 750.00)
IL-1548.95 (19.10 to 161.20)
TNF-α8.20 (3.40 to 55.50)
SecondaryPhase 1 and 2: Peak Serum Levels of Ferritin in Blood
Time frame:
Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion
Reported as:
Median · ng/mL
Phase 1 and 2: Peak Serum Levels of Ferritin in Blood
ng/mLPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
Phase 1 and 2: Peak Serum Levels of Ferritin in Blood1427.39 (219.92 to 23100)
SecondaryPhase 1 and 2: Peak Serum Levels of Interleukin-2 Receptor Alpha (IL-2Rα) in Blood
Time frame:
Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion
Reported as:
Median · ng/mL
Phase 1 and 2: Peak Serum Levels of Interleukin-2 Receptor Alpha (IL-2Rα) in Blood
ng/mLPhase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ
Phase 1 and 2: Peak Serum Levels of Interleukin-2 Receptor Alpha (IL-2Rα) in Blood17.75 (3.45 to 57.77)

Adverse events

Collected over Adverse Events: Up to 1.8 years; All-Cause Mortality: Enrollment up to 30 days after completion of the final dose of atezolizumab, or 24 months after the KTE-C19 infusion or until disease progression, whichever was longer (maximum duration: 6.2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)2/3 (66.7%)3/3 (100%)3/3 (100%)
Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)1/4 (25%)2/3 (66.7%)3/3 (100%)
Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)2/7 (28.6%)3/6 (50%)6/6 (100%)
Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)14/23 (60.9%)15/22 (68.2%)22/22 (100%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
EncephalopathyNervous system disorders2/31/31/64/22
AnaemiaBlood and lymphatic system disorders0/31/31/60/22
Lower gastrointestinal haemorrhageGastrointestinal disorders0/31/30/60/22
Obstruction gastricGastrointestinal disorders0/31/30/60/22
PneumoniaInfections and infestations1/30/30/61/22
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/30/60/22
SeizureNervous system disorders0/31/30/61/22
AspirationRespiratory, thoracic and mediastinal disorders0/31/30/60/22
HypoxiaRespiratory, thoracic and mediastinal disorders1/30/30/61/22
PneumothoraxRespiratory, thoracic and mediastinal disorders0/31/30/60/22
Most frequent other events
Showing 10 of 134
Most frequent other events
EventPhase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)
AnaemiaBlood and lymphatic system disorders2/33/34/613/22
FatigueGeneral disorders2/33/34/611/22
PyrexiaGeneral disorders3/33/36/621/22
EncephalopathyNervous system disorders3/31/32/67/22
HypotensionVascular disorders3/32/34/69/22
NauseaGastrointestinal disorders1/32/35/68/22
NeutropeniaBlood and lymphatic system disorders2/31/31/65/22
Sinus tachycardiaCardiac disorders1/31/34/610/22
Abdominal painGastrointestinal disorders2/32/32/63/22
ConstipationGastrointestinal disorders2/32/30/64/22

Baseline characteristics

The Safety Analysis Set included all participants treated with any dose of KTE-C19.

Age, Categorical
Age, Categorical(Participants)Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)Total
<=18 years00000
Between 18 and 65 years2261828
>=65 years11046
Age, Continuous
Age, Continuous(years)Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)Total
Mean56.0 ± 14.8042.7 ± 19.5053.2 ± 6.1858.4 ± 7.4056 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)Total
Female024814
Male3121420
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)Total
Hispanic or Latino11013
Not Hispanic or Latino2262030
Unknown or Not Reported00011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)Total
Asian10135
White2351828
Other00011
Region of Enrollment
Region of Enrollment(Participants)Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19)Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19)Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19)Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19)Total
United States3362234
08

Study locations

5 sites
  • City of Hope
    Duarte, California 91010, United States
  • Stanford Cancer Center
    Palo Alto, California 94305, United States
  • H Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Jacobson CA, Locke FL, Miklos DB, Herrera AF, Westin JR, Lee J, et al. End of Phase 1 results for ZUMA-6: Axicabtagene ciloleucel (axi-cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. Presented at ASH, 2018.
  • Locke FL, Westin JR, Miklos DB, Herrera AF, Jacobson CA, Lee J, et al. Phase 1 results from ZUMA-6: Axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. Presented at ASH, 2018, presentation #2628.
  • Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jan 2023, 75 months.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 75 months is close to that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2016
First posted
Oct 6, 2016
StartActual
Sep 29, 2016
Primary completionActual
Jan 12, 2023
CompletionActual
Jan 12, 2023
Results delay requested
Dec 9, 2019
Results first posted
Jun 26, 2020
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02926833
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 6, 2016
Start date
Sep 29, 2016
Primary completion
Jan 12, 2023
Completion
Jan 12, 2023
Results posted
Jun 26, 2020
Last update
Mar 6, 2024

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axicabtagene ciloleucel

Start the discussion